Bibliographic Info
GuidelineWHO consolidated guidelines on tuberculosis: module 4: treatment and care
Year of Publication2025
Issuing InstitutionWorld Health Organization
Recommendation
Status
Maintained
Recommended in favor
Conditional
Certainty of evidence
Very low
Longer regimens for multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB): In children with MDR/RR-TB aged below 6 years, an all-oral treatment regimen containing bedaquiline may be used.
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents.
Year2022
InstitutionWHO
Guideline
WHO consolidated guidelines on tuberculosis: Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update
Year2022
InstitutionWorld Health Organization